New York, NY—October 28, 2005
New research published today in the November 2005 issue of Arthritis & Rheumatism should offer hope to the more than two million Americans suffering from rheumatoid arthritis (RA) -- more than 75% of whom are women. A study conducted by researchers in the Netherlands sheds light on the best treatment strategy for a patient newly diagnosed with RA.
The study, which compared the four most commonly prescribed treatment strategies for early RA, showed that all four treatments resulted in measurable improvements in patients. However, those patients who received initial combination therapy had less disease progression and joint damage than the patients who received disease-modifying antirheumatic drugs (DMARDs) alone or step-up combination therapy.
“The study’s main message for patients is that RA needs to be diagnosed early and treated early and actively, and with medications capable of stopping joint damage. This study is supportive of early combination therapy, but more research is still needed,” said Theodore R. Fields, MD, FACP, clinical director of the Gosden Robinson Early Arthritis Center (EAC) at Hospital for Special Surgery (HSS) and Joseph A. Markenson, MD, director of rheumatoid arthritis clinical trials at HSS, in a joint statement.
The following doctors from the Gosden Robinson Early Arthritis Center at HSS are available to comment on this study and other early RA treatments:
Theodore R. Fields, MD, FACP
Clinical Director, Gosden Robinson Early Arthritis Center at Hospital for Special Surgery
Stephen DiMartino, MD
Associate Clinical Director, Gosden Robinson Early Arthritis Center at Hospital for Special Surgery
Melanie Harrison, MD
Research Director, Gosden Robinson Early Arthritis Center at Hospital for Special Surgery
Joseph A. Markenson, MD
Attending Physician, Hospital for Special Surgery
Stephen Paget, MD, FACP, FACR
Physician-in-Chief of the Department of Medicine, Division of Rheumatology, Hospital for Special Surgery
The Gosden Robinson Early Arthritis Center (EAC) at Hospital for Special Surgery (HSS) was founded to promote the early diagnosis and treatment of arthritis and to support research efforts to determine more effective treatment and prevention strategies. The EAC connects patients quickly and efficiently with a rheumatologist who can evaluate joint pain and start an appropriate course of treatment. The patient’s primary care physician is kept fully advised of findings and recommendations. HSS was recently ranked the number 2 in rheumatology in the annual “Best Hospitals” issue of U.S. News & World Report.
Results of the study can be found at: http://www.interscience.wiley.com/journal/arthritis
About Hospital for Special Surgery
Hospital for Special Surgery (HSS) is the world’s leading academic medical center focused on musculoskeletal health. HSS is nationally ranked No. 1 in orthopedics and No. 3 in rheumatology by U.S. News & World Report (2017-2018), and is the first hospital in New York State to receive Magnet Recognition for Excellence in Nursing Service from the American Nurses Credentialing Center four consecutive times. HSS has one of the lowest infection rates in the country. HSS is an affiliate of Weill Cornell Medical College and as such all Hospital for Special Surgery medical staff are faculty of Weill Cornell. The hospital's research division is internationally recognized as a leader in the investigation of musculoskeletal and autoimmune diseases. HSS has locations in New York, New Jersey and Connecticut.
For More Information: